Correlation Between Neuropace and PAVmed Series

Can any of the company-specific risk be diversified away by investing in both Neuropace and PAVmed Series at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and PAVmed Series into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neuropace and PAVmed Series Z, you can compare the effects of market volatilities on Neuropace and PAVmed Series and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of PAVmed Series. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and PAVmed Series.

Diversification Opportunities for Neuropace and PAVmed Series

-0.16

Correlation Coefficient

Neuropace  PAVmed Series

Good diversification

The 3 months correlation between Neuropace and PAVmed is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and PAVmed Series Z in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PAVmed Series Z and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with PAVmed Series. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PAVmed Series Z has no effect on the direction of Neuropace i.e., Neuropace and PAVmed Series go up and down completely randomly.

Pair Corralation between Neuropace and PAVmed Series

Given the investment horizon of 90 days Neuropace is expected to generate 16.22 times less return on investment than PAVmed Series. But when comparing it to its historical volatility, Neuropace is 12.25 times less risky than PAVmed Series. It trades about 0.16 of its potential returns per unit of risk. PAVmed Series Z is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  2.59  in PAVmed Series Z on September 15, 2024 and sell it today you would lose (1.09) from holding PAVmed Series Z or give up 42.08% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	45.31%
Values	Daily Returns

Neuropace  vs.  PAVmed Series Z

Neuropace

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace exhibited solid returns over the last few months and may actually be approaching a breakup point.

PAVmed Series Z

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in PAVmed Series Z are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating primary indicators, PAVmed Series showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Neuropace and PAVmed Series

The main advantage of trading using opposite Neuropace and PAVmed Series positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, PAVmed Series can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PAVmed Series will offset losses from the drop in PAVmed Series' long position.

The idea behind Neuropace and PAVmed Series Z pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.